The earnings reports for the biggest of Big Pharma are all in. Bayer reported last week, making it possible to see how they stacked up as they came into the new year. There are no big surprises. Pfizer and Merck, with ongoing patent issues and reorganizations, saw their positions fall a couple of notches, and AbbVie, having been spun off from Abbott Laboratories at the beginning of the year, didn't quite make the top 10. Its disappearance allowed Eli Lilly to make the list. It also helped Bayer HealthCare move up a couple of notches.
After the major patent crashes of 2012, last year was more of a transitional period. Johnson & Johnson, Novartis, Roche, GlaxoSmithKline, Eli Lilly and Bayer saw their revenues rise, although only J&J and Bayer had an appreciable change. Bayer's pharma revenues, combined with its consumer health unit, saw revenue growth of 7.6% based on dollars. J&J's number was up 6.7%, driven in large part by its pharma division. The others were flat or had growth of less than 3%.
Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug prices surge ever higher, spurring a growing backlash from payers.
In this constantly shifting panorama you'll find a group of executives who are forging new paths for others to follow. This year, the third for Fierce, we present the men and women whose influence is being felt across the industry.
Influence, of course, isn't always a force for good. But it can be. To be truly influential in an industry, you need to be able to persuasively explain new methods that can exert a powerful hold on colleagues in the same global field. Some of this year's group have excelled in that regard.
We hope you enjoy this year's report. And please offer any suggestions you may have for next year's project on the influentials.
Layoffs are always big news in pharma, as they are seen as an indicator of the health of the industry. Companies don't like to have to announce them, but when they decide to, getting plenty of attention becomes important. That is to impress upon investors that their CEOs are making the hard decisions needed to keep costs in line. Of course employees are interested. They know from the inside what is about to happen, and having lived through the awful anticipation, they want to see what the carnage is really going to be.
The patent cliff is often the big culprit. One might think that a one-to-one relationship could be graphed between what is happening with the patent cliff and layoffs, but that is not the case. Pharma analysis company EvaluatePharma has forecast that there were $41 billion in patent sales at risk in 2011, a year in which the top 10 pharma layoffs amounted to 26,500. In 2012, the peak year, EvalutePharma said a whopping $67 billion was at risk. In that year, the top layoffs tallied more than 34,600. Then in 2013, when at-risk sales fell to only $29 billion, we have a total for the top 10 of nearly 27,900.
This is the best FiercePharma reading experience we've ever created. Swipe right-to-left within articles to quickly scan the latest news. Get breaking news alerts sent to your mobile device so you're the first to know when a major story unfolds. Download it today; the app is an essential complement to our e-mail newsletter and website.
Have something to say? Join the conversation at
FiercePharma's LinkedIn group.
POPULAR COMMENT THREADS
India's Ranbaxy Laboratories has issued another recall for its generic Lipitor, but a series of product recalls in recent weeks have come from plants around the world and companies as varied as Pfizer, Mylan and Gilead Sciences.
AstraZeneca may get lucky with Nexium. That's thanks to the embattled Ranbaxy Laboratories, the Indian generics maker that could launch a copycat version May 27.
Following a huge outcry from drugmakers, insurance companies, and patient advocates, the Obama administration said Monday it had abandoned proposed changes to the Medicare Part D drug benefit.
Bayer and Onyx Pharmaceuticals' Nexavar has seen a lot of success as a liver-cancer treatment, topping market threats from the likes of Bristol-Myers Squibb and Pfizer in head-to-head trials on its way to blockbuster status. But as an adjuvant therapy for liver cancer? It could be awhile--if ever. Tuesday, the drug missed its target in a Phase III trial, failing to meet the study's main goal of improving recurrence-free survival.
The number of new drugs approved by the FDA last year may have been down considerably but some of them were humdingers. Eight are projected to hit blockbuster status 5 years out, and the entire group of 33 is forecast to have fifth-year projected sales of $25.4 billion. That is 50% more than the record breaking group of 43 drugs approved in 2012.
A British drugmaker has landed in the middle of the controversy over Sweetwater, Texas' Rattlesnake RoundUp.
From Our Sister Sites
Pfizer, which boosted production at its plant in Indonesia in 2012, is expanding there again.
With a shortage of ingredients for essential pain drugs looming, there is a fight going on in Australia over whether production of opium poppies can be widened from the island of Tasmania, the source of about half the world's supply.